Barry  Canton net worth and biography

Barry Canton Biography and Net Worth

Major Shareholder of Ginkgo Bioworks
Barry is responsible for overall foundry technology strategy and direction. He holds a PhD in Biological Engineering from MIT, where his thesis focused on refinement of standard biological parts and the interactions between a host cell and an engineered genetic circuit. At MIT, he was involved with the Synthetic Biology Working Group that was instrumental in catalyzing the new field. He also holds an MEngSc in Mechanical Engineering from University College Dublin.

What is Barry Canton's net worth?

The estimated net worth of Barry Canton is at least $82.48 million as of December 20th, 2023. Dr. Canton owns 12,374,554 shares of Ginkgo Bioworks stock worth more than $82,476,402 as of March 27th. This net worth estimate does not reflect any other assets that Dr. Canton may own. Learn More about Barry Canton's net worth.

How do I contact Barry Canton?

The corporate mailing address for Dr. Canton and other Ginkgo Bioworks executives is 955 Fifth Avenue, New York NY, 10075. Ginkgo Bioworks can also be reached via phone at 877-442-5362 and via email at investors@ginkgobioworks.com. Learn More on Barry Canton's contact information.

Has Barry Canton been buying or selling shares of Ginkgo Bioworks?

Barry Canton has not been actively trading shares of Ginkgo Bioworks within the last three months. Most recently, Barry Canton sold 37,650 shares of the business's stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $1.79, for a transaction totalling $67,393.50. Following the completion of the sale, the insider now directly owns 12,374,554 shares of the company's stock, valued at $22,150,451.66. Learn More on Barry Canton's trading history.

Who are Ginkgo Bioworks' active insiders?

Ginkgo Bioworks' insider roster includes Barry Canton (Major Shareholder), Marijn Dekkers (Director), Mark Dmytruk (Insider), Christian Henry (Director), Jason Kelly (Insider), Reshma Shetty (Insider), and Harry Sloan (Director). Learn More on Ginkgo Bioworks' active insiders.

Are insiders buying or selling shares of Ginkgo Bioworks?

In the last twelve months, Ginkgo Bioworks insiders bought shares 1 times. They purchased a total of 297,619 shares worth more than $270,833.29. In the last twelve months, insiders at the sold shares 11 times. They sold a total of 410,143 shares worth more than $348,274.49. The most recent insider tranaction occured on March, 4th when insider Steven P Coen sold 395 shares worth more than $3,049.40. Insiders at Ginkgo Bioworks own 9.7% of the company. Learn More about insider trades at Ginkgo Bioworks.

Information on this page was last updated on 3/4/2025.

Barry Canton Insider Trading History at Ginkgo Bioworks

Barry Canton Buying and Selling Activity at Ginkgo Bioworks

This chart shows Barry Canton's buying and selling at Ginkgo Bioworks by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Ginkgo Bioworks Company Overview

Ginkgo Bioworks logo
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $6.67
Low: $6.59
High: $7.13

50 Day Range

MA: $10.58
Low: $6.46
High: $16.38

2 Week Range

Now: $6.67
Low: $5.26
High: $48.00

Volume

1,311,192 shs

Average Volume

1,419,755 shs

Market Capitalization

$386.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23